Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Observational Study Finds Sanofi’s Diabetes Drug Lowers Incidence of Hypoglycemia

XTALKS VITALS NEWS

According to the researchers – who presented at the Endocrine Society 2017 Annual Meeting – diabetic patients taking Toujeo experienced fewer hypoglycemic events, without loss of blood sugar control.

Share this!

April 4, 2017 | by Sarah Hand, M.Sc.

Data from a recent real-world observational study has found that that Sanofi’s type 2 diabetes drug, Toujeo (insulin glargine 300 Units/mL), was associated with a lower risk of hypoglycemia, compared to other basal insulins. According to the researchers – who presented at the Endocrine Society 2017 Annual Meeting – diabetic patients taking Toujeo experienced fewer hypoglycemic events, without loss of blood sugar control.

The observational study – DELIVER 1 – analyzed the electronic medical records for nearly 1,900 type 2 diabetic patients. For the purposes of comparative analysis, patients were equally split into two cohorts: patients that switched from basal insulin to Toujeo, and patients that switched from one basal insulin to another.

Using data collected one year before the medication switch, and six months after, the researchers compared the average change in blood sugar levels, occurrence of hypoglycemia, and the incidence of hypoglycemia-related inpatient or emergency room visits. Diabetic patients who switched from basal insulin to Toujeo showed fewer hypoglycemic events, compared those who switched to another basal insulin.



What’s more, the reduced rate of hypoglycemic events was not associated with a compromise in blood sugar control in patients taking Toujeo. Patients taking Toujeo also experienced a nearly 50 percent reduction in inpatient or emergency room visits associated with hypoglycemic events.

“These results increase the body of evidence on the use of Toujeo in people with type 2 diabetes from observational studies,” said Riccardo Perfetti, Head of Global Diabetes Medical Team, ‎Sanofi. “While randomized clinical trials provide the highest level of evidence, comparative data from real-world observational studies can be relevant for payors and other organizations evaluating how findings from clinical trials can translate into routine clinical practice.”

Toujeo was approved by the US Food and Drug Administration (FDA) over two years ago, in February of 2015. In the fourth quarter of 2016, Toujeo sales totaled €238 million, with €169 million generated in the US market alone.

“Sanofi is committed to going beyond traditional models to conduct further studies to assess Toujeo, combining the broad populations, and type of interaction between healthcare professionals and patients seen in routine care with the rigorous methodology of clinical trials,” said Perfetti. “The randomized Real Life Study program will provide further evidence that directly reflects Toujeo's performance in standard clinical practice.”


Keywords:  Observational Study, Diabetes, Insulin


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Canadian Regulator Recalls Pie Shells Over E. Coli Contaminated Flour

April 28, 2017 - Multiple brands of pie and tart shells are being recalled in Canada after the flour used to manufacture them was linked to 28 cases of illness due to infection with E. coli O121.

Featured In: Food News


FDA Sends Warning Letters to Manufacturers of Fake Cancer Drugs

April 27, 2017 - The FDA is cracking down on the sale of illegal cancer drugs by sending warning letters to 14 US companies selling the unapproved products.

Featured In: Life Science News, Drug Safety News


Womb-Like Device Could Increase Survival of Premature Babies

April 27, 2017 - Researchers at the Children's Hospital of Philadelphia (CHOP) have developed a womb-like device which mimics the environmental conditions found inside the uterus.

Featured In: Life Science News, Medical Device News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

What Medical Device Manufacturers Need to Know Before Developing a Biological Safety Evaluation

REGISTER FOR THESE WEBINARS

Technology Solutions for Late Phase Research: Optimising Real World Data Assets


Serialization for Late Starters – With Live Industry Research Results


Clinical Not All Antioxidants Are Created Equal: Astaxanthin, The Antioxidant Powerhouse


The New Gold Standards of IRT Delivery for Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.